On January 5, 2024, GlycoEra AG closed the transaction. The company amended the terms of transaction. The transaction included participation from new investor, Bristol-Myers Squibb Company, returning investors, Sofinnova Partners SAS, 5AM Venture Management, LLC, and Roche Venture Fund.
Market Closed -
Other stock markets
|
After market 02:02:06 am | |||
41.2 USD | +2.62% |
|
40.96 | -0.57% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.70% | 81.39B | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- GlycoEra AG announced that it has received funding from Sofinnova Partners SAS, 5AM Venture Management, LLC, Roche Venture Fund, LimmaTech Biologics AG, Bristol-Myers Squibb Company